Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 906843, 7 pages
Clinical Study

Clinical Efficacy of Moringa oleifera Lam. Stems Bark in Urinary Tract Infections

1Ayurvedic Pharmacy Laboratory, Banaras Hindu University, Rajiv Gandhi South Campus, Barkachha, Mirzapur 231001, India
2Department of Dravyaguna, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India

Received 20 May 2014; Revised 6 August 2014; Accepted 2 September 2014; Published 2 November 2014

Academic Editor: Beata Olas

Copyright © 2014 Santosh Kumar Maurya and Anil Kumar Singh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Urinary tract infections (UTI) are the most common problem in clinical practice. Usually they are asymptomatic and are commonly present with distressing symptoms like pain and burning sensation on urination. Antibiotics are widely used to treat UTIs; however, they have their own limitations like resistance, reinfection, and relapses. The purpose of the current study was to evaluate the value of Moringa oleifera Lam. stem bark as a potential medicine for UTIs. Study Design. 30 patients with UTI were randomly divided into two groups with 15 patients in each group. Shigru bark was given to patients of the first group (trial group) and modern medicines were prescribed to the other group of patients. At least three follow-ups are taken in both groups at the end of every week of treatment. Results. After treatment 66.67 % were cured, 13.33 % improved, 13.33% patients have no change, and 6.67% relapsed in trial group and in control group 46.67% were cured, 26.66% improved, 6.67% patients have no change, and 20% relapsed. Interpretation and Conclusion. The trial drug is significant in the management of UTI. This study needs to be done on a large scale and for a long time.